

New/Changed Dose**Allergy/Asthma (E-Z) Ebglyss™, Ilaris®, Nucala®, Rinvoq™, Xolair®****Prescriber Information**

Prescriber Name _____ MD DO NP PA NPI _____
 Office Contact _____ Practice Name / Collaborating MD _____
 Address _____ City _____ State _____ Zip _____
 Phone _____ Fax _____

Patient Information • PLEASE SEND COPY OF INSURANCE CARD

Patient's Name _____ Last 4 Digits of SS# _____ DOB / /
 Sex M F Weight _____ Height _____ Diabetic? Y N
 Address _____ City _____ State _____ Zip _____
 Home Phone _____ Work/Cell _____ HIPAA Contact _____
 Emergency # _____
 Interpreter Needed? Y N | Allergies Y N If Yes, list allergies _____

Insurance Information

Primary Insurance _____ Policy ID _____ Group# _____
 BIN _____ PCN _____
 Policyholder Name _____ Policyholder DOB / /

Clinical Information • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES, AND LAB VALUES

ICD-10/Diagnosis Code Pulmonary Eosinophilia (J82) Moderate Persistent Asthma, uncomplicated (J45.40) Severe Persistent Asthma, uncomplicated (J45.50) Idiopathic Urticaria (L50.1)
 Atopic Dermatitis (L20.9) Nasal Polyp (J33._____) Eosinophilic esophagitis (K20)
 Other _____ FEV1 _____ %

Pre-treatment serum IgE < 30 IU/mL ≥30-100 IU/mL > 100-200 IU/mL > 200-300 IU/mL
 > 300-400 IU/mL > 400-500 IU/mL > 500-600 IU/mL > 600-700 IU/mL

Patient medical history includes Positive RAST Positive skin test to perennial aeroallergen
 Asthma with eosinophilic phenotype Other _____

Current maintenance treatment (include dose and frequency) _____

Current exacerbation treatment (include dose and frequency) _____

Patient is a smoker or is exposed to smoke in the home Y N

Prior Treatment? Y N (Provide Information Below) BSA Affected (%) _____

Affected Areas Palms Soles Head Neck Genitalia Other _____

Prior Therapy _____

Reason for Discontinuation of Therapy _____ Approx. Start Date / /

Approx. End Date / /

Comorbidities _____

Concomitant Medications _____

Prescription Information

Medication	Quantity/Dose	Sig	Refills
EBGLYSS™	QS for appropriate month of starter dose schedule	Starter Dose Inject 500 mg (two 250 mg injections) SQ at week 0 and 2, then 250 mg SQ every 2 weeks until 16 or later (when adequate clinical response is achieved)	4 Refills
	1 carton (1x250 mg/2 ml)	Maintenance Dose Inject 250 mg SQ every 4 weeks	
NUCALA® *Asthma (12 years and older) & CRSwNP (adults) Pen PFS	1 carton (1x100 mg/ml)	Inject 100 mg SQ once every 4 weeks	
NUCALA® *HES (patients 12 years and older) and EGPA (adults) Pen PFS	3 cartons (3x100 mg/ml)	Inject 300 mg SQ once every 4 weeks	
RINVOQ™	15 mg tablet (30 day supply) 30 mg tablet (30 day supply)	Take 1 tablet by mouth daily	
XOLAIR® *Pen only for use in ages 12+ Pen PFS	Number of 75 mg/0.5 ml pens/syringes _____ Number of 150 mg/ml pens/syringes _____ Number of 300 mg/2 ml pens/syringes _____	Inject _____ mg SQ once every _____ weeks	

Injection Training

Patient received injection training _____ Prescriber's office to provide injection training
 Community Memorial Healthcare to coordinate injection training

By signing this form and utilizing our services, you are authorizing Community Memorial Healthcare and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

Prescriber Signature _____

Substitution Permitted

Date _____

Prescriber Signature _____

Dispense as Written

Date _____

If brand is required, please write "DAW" in the box to the right.